MENU

GERN Stock Tickeron detected bullish Stock Pattern: Head-and-Shoulders Bottom GERN on May 19, 2025, netting in a 12.98% gain over 3 weeks

A.I.dvisor
at Tickeron.com
Loading...
+12.98% Gain from a Successful pattern Head-and-Shoulders Bottom
GERN - Geron Corp
Tickeron
Ticker: GERN
Company: Geron
Gain: +12.98%
Confirmed: 05/19/25
Succeeded: 05/29/25
Total length: 22 days
On May 07, 2025, A.I.dvisor detected a Head-and-Shoulders Bottom Pattern (Bullish) for Geron Corp (GERN, $1.31). On May 19, 2025, A.I.dvisor confirmed the Bullish pattern, setting a target price of $1.57. 10 days later, on May 29, 2025, GERN reached the target price resulting in a +1 for traders who took a long position in the stock.

GERN's RSI Indicator climbs out of oversold territory

The RSI Oscillator for GERN moved out of oversold territory on May 12, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In of the 27 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 20, 2025. You may want to consider a long position or call options on GERN as a result. In of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for GERN just turned positive on May 16, 2025. Looking at past instances where GERN's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .

GERN moved above its 50-day moving average on May 22, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for GERN crossed bullishly above the 50-day moving average on May 30, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GERN advanced for three days, in of 219 cases, the price rose further within the following month. The odds of a continued upward trend are .

GERN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GERN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. GERN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.693) is normal, around the industry mean (16.332). P/E Ratio (0.000) is within average values for comparable stocks, (59.787). GERN's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.227). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (8.850) is also within normal values, averaging (263.647).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GERN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
GERN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of therapeutic products for cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
919 East Hillsdale Boulevard
Phone
+1 650 473-7700
Employees
141
Web
https://www.geron.com